Cigna updated Ofev (nintedanib) coverage to an indication‑specific, 1‑year approval structure for IPF, progressive pulmonary fibrosis (chronic fibrosing ILDs with a progressive phenotype), and SSc‑ILD with separate pathways for new starts and patients already on therapy. All indications now require age ≥18, documentation of baseline or current FVC percent predicted (threshold ≥40%), specialty prescribing/consultation (pulmonologist for IPF; pulmonologist or rheumatologist for non‑IPF and SSc‑ILD), and radiographic confirmation where specified (HRCT or surgical lung biopsy for IPF; HRCT for SSc‑ILD). Continuation approvals require documented clinical benefit over the prior year. Use of Ofev outside the three FDA‑labeled indications and concomitant use with Esbriet (pirfenidone) are considered not medically necessary.
March 15, 2026 Revision: Indication‑Specific 1‑Year Approval Structure
Summary of revisions in this version
This revision adopts the updated coverage framework for Ofev (nintedanib) with clear, indication-specific approval pathways tied to FDA-labeled uses: Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (chronic fibrosing ILDs with a progressive phenotype), and Interstitial Lung Disease associated with Systemic Sclerosis (SSc-ILD). Approvals are structured as 1-year authorizations with separate criteria for initial therapy versus patients currently receiving Ofev.
Notable structured requirements were emphasized in this edition: documentation of baseline or current Forced vital capacity (FVC) percent predicted for all indications, radiographic confirmation for IPF and SSc-ILD (HRCT or surgical lung biopsy for IPF; HRCT for SSc-ILD), and prescriber specialty involvement (pulmonologist for IPF; pulmonologist or rheumatologist for non-IPF fibrosing ILD and SSc-ILD). The policy also reiterates that concomitant use of Ofev with Esbriet (pirfenidone) is considered not medically necessary.
Authorized Use Criteria for `Idiopathic Pulmonary Fibrosis`
Idiopathic Pulmonary Fibrosis (IPF) coverage criteria
For IPF, the policy permits a 1-year approval under two pathways: initial therapy or continuation for patients already receiving Ofev. Initial approvals require patients to be ≥ 18 years, have baseline FVC ≥ 40% predicted, and a confirmed diagnosis by either HRCT demonstrating a usual interstitial pneumonia pattern or a surgical lung biopsy showing UIP. Medication must be prescribed by or in consultation with a pulmonologist, and a preferred product criterion is referenced for formulary considerations.
Continuation approvals for current Ofev users require age ≥ 18, documentation of a beneficial response over the last year (or from baseline if <1 year of therapy), and pulmonologist prescribing/consultation. Examples of beneficial responses listed include reduced anticipated decline in FVC, six-minute walk distance, or fewer/severe IPF exacerbations.
Coverage for Chronic Fibrosing ILDs with a Progressive Phenotype
Progressive Pulmonary Fibrosis / chronic fibrosing ILDs with a progressive phenotype
The policy covers Progressive Pulmonary Fibrosis (terms used interchangeably with chronic fibrosing ILDs with a progressive phenotype) with a 1-year approval pathway for initial and continuing therapy. Initial approval requires age ≥ 18, FVC ≥ 40% predicted, provider-documented fibrosing disease affecting >10% lung volume on HRCT, and clinical signs of progression (examples include FVC decline ≥10%, or FVC decline 5–<10% with worsening symptoms or imaging). Medication must be prescribed by or in consultation with a pulmonologist or rheumatologist.
For patients already on Ofev, continued coverage requires age ≥ 18, evidence of beneficial response over the prior year (or from baseline if <1 year), and specialty prescribing/consultation. The policy aligns the trial inclusion criteria (e.g., INBUILD) with clinical entry conditions such as FVC ≥ 45% and DLCO limits noted in the efficacy discussion, though the explicit coverage threshold used in the criteria is FVC ≥ 40% predicted.
SSc‑ILD Criteria and Explicit Non‑Coverage (including combination therapy)
Systemic Sclerosis‑Associated Interstitial Lung Disease (SSc‑ILD) coverage criteria and exclusions
For SSc‑ILD, the policy provides 1-year approvals for initial and continuing therapy. Initial therapy requires age ≥ 18, FVC ≥ 40% predicted, HRCT-confirmed diagnosis (≥10% fibrosis described in the efficacy section), and prescription by or consultation with a pulmonologist or rheumatologist. Continuation mirrors other indications: documented benefit over the prior year and specialty prescribing/consultation.
The policy explicitly lists conditions considered not medically necessary: use of Ofev for indications outside the three FDA-approved categories, and concomitant use of Ofev with Esbriet (pirfenidone) due to insufficient evidence on safety and effectiveness of the combination. The document references guideline caution and a small exploratory study but maintains the combination as excluded from coverage.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.